GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

GH Research (NASDAQ:GHRS) had its price target increased by Needham & Company LLC from $31.00 to $32.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 110.94% from the company’s current price.

A number of other research firms have also weighed in on GHRS. Guggenheim reaffirmed a “buy” rating and issued a $29.00 price objective on shares of GH Research in a research note on Monday, January 5th. Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Citigroup reiterated a “market outperform” rating on shares of GH Research in a report on Tuesday, January 6th. TD Cowen restated a “buy” rating on shares of GH Research in a report on Monday, January 5th. Finally, Royal Bank Of Canada increased their price target on GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, GH Research has an average rating of “Moderate Buy” and an average target price of $39.13.

GH Research Price Performance

GHRS opened at $15.17 on Friday. The company has a 50 day simple moving average of $15.38 and a two-hundred day simple moving average of $14.21. The firm has a market cap of $789.26 million, a P/E ratio of -20.50 and a beta of 1.00. GH Research has a 1-year low of $7.98 and a 1-year high of $19.51.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, March 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. Equities analysts anticipate that GH Research will post -0.8 earnings per share for the current year.

Institutional Trading of GH Research

Several institutional investors have recently bought and sold shares of GHRS. Barclays PLC raised its holdings in shares of GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after acquiring an additional 822 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of GH Research during the 4th quarter worth $38,000. Osaic Holdings Inc. boosted its stake in GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of GH Research in the 2nd quarter worth approximately $79,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of GH Research in the 2nd quarter worth approximately $89,000. 56.90% of the stock is owned by institutional investors and hedge funds.

Key GH Research News

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: Company beat quarterly estimates and reported solid year‑end cash: GH Research reported $0.23 loss per share vs. a consensus -$0.29 (better-than-expected), completed and presented Phase 2b GH001 data, obtained FDA clearance to begin U.S. clinical investigation, and ended 2025 with $280.7M in cash and marketable securities. GH Research Reports Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Broker support and price‑target action: HC Wainwright reaffirmed a Buy and market commentary published this week included a $70 price target, which is a materially higher target than the current share price and provides bullish analyst support. GH Research (NASDAQ:GHRS) Price Target Raised to $70.00
• Positive Sentiment: Longer‑term estimate improvement: HC Wainwright nudged its FY2029 EPS estimate slightly better (from -$1.12 to -$1.02), signalling some incremental optimism on longer‑horizon economics. (Source: HC Wainwright research notes)
• Neutral Sentiment: Short interest data is effectively meaningless/noisy right now — reported short interest showed 0 shares (with NaN change), implying no actionable short‑interest signal given the data anomalies and very low days‑to‑cover figure.
• Negative Sentiment: Analyst cuts to near‑ and medium‑term EPS: HC Wainwright lowered several forecasts (Q4 2025, FY2025, FY2026, FY2027 and FY2028 EPS were revised lower), which weakens near‑term profitability expectations and helps explain downward pressure despite balanced positives above. HC Wainwright Comments on GH Research FY2030 Earnings

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.